<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_CGU_Taiwan skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:CGU Taiwan</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><HEADER class="top"><DIV class="header-subnav"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan">HOME</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Achievements">ACHIEVEMENTS</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Description">PROJECT</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Software">MODELING</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices">HUMAN PRACTICES</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Team">PEOPLE</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Interlab">INTERLAB</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Safety">SAFETY</A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Parts">PARTS</A></LI></DIV></HEADER><DIV class="mid"><DIV style="font-size:60px;color:#140731;text-decoration:none;margin-left:45%;">
Abstract
</DIV><B style="color:black;font-size:25px;margin-left:10%;">Leijuvant- A Revolutionary Choice of Vaccine Helper</B><DIV style="color:black;font-size:18px;margin-left:10%;text-align:justify;">
For many infectious diseases that still donâ€™t have an effective vaccine, enhancing T cell immune response may be the key point to solve this problem. Leijuvant represents a whole new perspective of adjuvant that uses Leishmania as an effective T cell stimulator. Leishmania is a parasite that specifically lives within macrophage, a professional antigen presenting cell (APC). As a potential vaccine adjuvant, Leishmania possess many advantages, including APC recruitment, pattern recognition receptor (PRR) activation, inflammasome activation, activation of MHC-presenting pathway and most important of all, T cell activation. Genetically-engineered Leishmania that can be inactivated by light exposure acts as a safe carrier to deliver specific antigens to APCs for activation of T cells and B cell stimulation. Based on this concept, we established a new model system to generate antigen-specific Leishmania adjuvant-- Leijuvant. We further designed a user-friendly MHC peptide prediction software to integrate key protein information and optimize the presentation of antigen peptides by MHC molecules. Our ultimate goal is to introduce Leijuvant as an effective, safe, and antigen-specific adjuvant to the vaccine industry and the general public.
</DIV></DIV><DIV class="mid2" style="background-color:#d0d0d0;top:130%;"><DIV style="font-size:60px;color:#140731;margin-left:35%;margin-top:2%;">
Start the Journey
</DIV><A href="https://2016.igem.org/Team:CGU_Taiwan/Description"><H2 style="font-size:35px;color:#140731;position:absolute;left:15%;top:490px;z-index:+1;text-decoration:none;">PROJECT</H2></A><A href="http://facebook.com/igemcgu"><H3 style="font-size:35px;color:#140731;position:absolute;left:45%;top:490px;text-decoration:none;">NEWS</H3></A><A href="https://2016.igem.org/Team:CGU_Taiwan/Results"><H4 style="font-size:35px;color:#140731;position:absolute;left:72%;top:490px;text-decoration:none;">RESULTS</H4></A></DIV><DIV class="end" style="top:190%;"><DIV style="font-size:20px;color:white;text-decoration:none;margin-left:20%;margin-top:5%;">
Chang Gung University
</DIV><DIV style="color:white;font-size:15px;margin-left:10%;text-align:justify;">
No.259, Wenhua 1st Rd., Guishan Dist., Taoyuan City 33302, Taiwan (R.O.C.)

TEL: +886-3-2118800 FAX:+886-3-2118700
</DIV></DIV><DIV class="end2" style="top:210%;"><UL class="list3" class="margin-left:1%;margin-top:2%;"><LI><A href="#anchor1"><B style="color:white;font-size:28px;margin-left:7%;">TOP</B></A></LI></UL><DIV class="sitemap" style="margin-left:5%;"><B style="color:white;font-size:28px;margin-top:5%;margin-left:4%;text-decoration:none;">SITE MAP</B></DIV><DIV class="sitemap" style="margin-left:22%;margin-top:-1%;"><UL class="list" class="margin-left:5%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan"><B style="color:white;font-size:18px;margin-left:20%;">HOME</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Achievements"><B style="color:white;font-size:18px;margin-left:20%;">ACHIEVEMENTS</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Interlab"><B style="color:white;font-size:18px;margin-left:20%;">INTERLAB</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Safety"><B style="color:white;font-size:18px;margin-left:20%;">SAFETY</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Parts"><B style="color:white;font-size:18px;margin-left:20%;">PARTS</B></A></LI></UL></DIV><DIV class="sitemap" style="margin-left:40%;margin-top:-2%;"><UL class="list" class="margin-left:5%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Description"><B style="color:white;font-size:18px;margin-left:20%;">PROJECT</B></A></LI><UL class="list2" class="margin-left:6%;margin-top:50%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Design"><B style="color:white;font-size:17px;margin-left:10%;">Design</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Background"><B style="color:white;font-size:17px;margin-left:10%;">Background</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Results"><B style="color:white;font-size:17px;margin-left:10%;">Results</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Proof"><B style="color:white;font-size:17px;margin-left:10%;">Proof</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Notebook"><B style="color:white;font-size:17px;margin-left:10%;">Notebook</B></A></LI></UL></UL></DIV><DIV class="sitemap" style="margin-left:55%;margin-top:-3.5%;"><UL class="list" class="margin-left:5%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices"><B style="color:white;font-size:18px;margin-left:20%;">HUMAN PRACTICES</B></A></LI><UL class="list2" class="margin-left:6%;margin-top:50%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Survey"><B style="color:white;font-size:17px;margin-left:10%;">Survey</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Education"><B style="color:white;font-size:17px;margin-left:10%;">Education</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Human_Practices_Communication"><B style="color:white;font-size:17px;margin-left:10%;">Communication</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Entrepreneurship"><B style="color:white;font-size:17px;margin-left:10%;">Entrepreneurship</B></A></LI></UL></UL></DIV><DIV class="sitemap" style="margin-left:75%;margin-top:-3.5%;"><UL class="list" class="margin-left:5%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Software"><B style="color:white;font-size:18px;margin-left:20%;">MODELING</B></A></LI><UL class="list2" class="margin-left:6%;"><LI><A href="http://163.25.92.36/igemcgu/igemwebhome.htm"><B style="color:white;font-size:17px;margin-left:10%;">McHug</B></A></LI></UL></UL><UL class="list" class="margin-left:1%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Team"><B style="color:white;font-size:18px;margin-left:20%;">OUR TEAM</B></A></LI><UL class="list2" class="margin-left:6%;margin-top:-5%;"><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Collaborations"><B style="color:white;font-size:17px;margin-left:10%;">Collaborations</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Attributions"><B style="color:white;font-size:17px;margin-left:10%;">Attributions</B></A></LI><LI><A href="https://2016.igem.org/Team:CGU_Taiwan/Team#anchor2"><B style="color:white;font-size:17px;margin-left:10%;">Sponsors</B></A></LI></UL></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>